Nicholas J Pastis1, Travis J Greer2, Nichole T Tanner2, Amy E Wahlquist3, Leonie L Gordon4, Anand K Sharma5, Nicholas C Koch5, Gerard A Silvestri2. 1. Division of Pulmonary/Critical Care, Medical University of South Carolina, Charleston, SC. Electronic address: pastisn@musc.edu. 2. Division of Pulmonary/Critical Care, Medical University of South Carolina, Charleston, SC. 3. Public Health Services, Medical University of South Carolina, Charleston, SC. 4. Department of Radiology, Medical University of South Carolina, Charleston, SC. 5. Department of Radiation Oncology, Medical University of South Carolina, Charleston, SC.
Abstract
BACKGROUND: Although stereotactic body radiation therapy (SBRT) is an established treatment option for early-stage lung cancer, there are no guidelines for reassessing patients for local treatment failure or intrathoracic recurrence after treatment. This study reports the sensitivity, specificity, and positive and negative predictive values for 18F-fluorodeoxyglucose (FDG) PET-CT scanning when used to evaluate patients after SBRT. METHODS: Charts were reviewed of all patients who received SBRT and a subsequent FDG PET-CT scan at a university hospital over a 5-year period. Pretreatment and 3-month posttreatment tumor characteristics on PET-CT scan and outcome data (adverse events from SBRT, need for repeat biopsy, rate of local treatment failure and recurrent disease, and all-cause mortality) were recorded. RESULTS: Eighty-eight patients were included in the study. Fourteen percent of patients (12 of 88) had positive 3-month PET scans. Of the positive results, 67% (eight of 12) were true positives. Eighty-six percent (76 of 88 patients) had negative 3-month FDG PET-CT scans, with 89% (68 of 76) true negatives. FDG PET-CT scan performed 3 months after SBRT for non-small cell lung cancer (NSCLC) had a sensitivity of 50% (95% CI, 0.26-0.75), a specificity of 94% (95% CI, 0.89-1.0), a positive predictive value of 67% (95% CI, 0.4-0.93), and a negative predictive value of 89% (95% CI, 0.83- 0.96). CONCLUSIONS: FDG PET-CT scan 3 months after treatment of NSCLC with SBRT was a specific but insensitive test for the detection of recurrence or treatment failure. Serial CT scans should be used for early surveillance following SBRT, whereas FDG PET-CT scans should be reserved to define suspected metastatic disease or to evaluate new abnormalities on CT scan, or for possible reassessment later in the follow-up period after radiation-related inflammation subsides.
BACKGROUND: Although stereotactic body radiation therapy (SBRT) is an established treatment option for early-stage lung cancer, there are no guidelines for reassessing patients for local treatment failure or intrathoracic recurrence after treatment. This study reports the sensitivity, specificity, and positive and negative predictive values for 18F-fluorodeoxyglucose (FDG) PET-CT scanning when used to evaluate patients after SBRT. METHODS: Charts were reviewed of all patients who received SBRT and a subsequent FDG PET-CT scan at a university hospital over a 5-year period. Pretreatment and 3-month posttreatment tumor characteristics on PET-CT scan and outcome data (adverse events from SBRT, need for repeat biopsy, rate of local treatment failure and recurrent disease, and all-cause mortality) were recorded. RESULTS: Eighty-eight patients were included in the study. Fourteen percent of patients (12 of 88) had positive 3-month PET scans. Of the positive results, 67% (eight of 12) were true positives. Eighty-six percent (76 of 88 patients) had negative 3-month FDG PET-CT scans, with 89% (68 of 76) true negatives. FDG PET-CT scan performed 3 months after SBRT for non-small cell lung cancer (NSCLC) had a sensitivity of 50% (95% CI, 0.26-0.75), a specificity of 94% (95% CI, 0.89-1.0), a positive predictive value of 67% (95% CI, 0.4-0.93), and a negative predictive value of 89% (95% CI, 0.83- 0.96). CONCLUSIONS:FDG PET-CT scan 3 months after treatment of NSCLC with SBRT was a specific but insensitive test for the detection of recurrence or treatment failure. Serial CT scans should be used for early surveillance following SBRT, whereas FDG PET-CT scans should be reserved to define suspected metastatic disease or to evaluate new abnormalities on CT scan, or for possible reassessment later in the follow-up period after radiation-related inflammation subsides.
Authors: Robert Timmerman; Rebecca Paulus; James Galvin; Jeffrey Michalski; William Straube; Jeffrey Bradley; Achilles Fakiris; Andrea Bezjak; Gregory Videtic; David Johnstone; Jack Fowler; Elizabeth Gore; Hak Choy Journal: JAMA Date: 2010-03-17 Impact factor: 56.272
Authors: J Dinkel; O Khalilzadeh; C Hintze; M Fabel; M Puderbach; M Eichinger; H-P Schlemmer; M Thorn; C P Heussel; M Thomas; H-U Kauczor; J Biederer Journal: Lung Cancer Date: 2013-08-08 Impact factor: 5.705
Authors: Henri G Colt; Septimiu D Murgu; Robert J Korst; Christopher G Slatore; Michael Unger; Silvia Quadrelli Journal: Chest Date: 2013-05 Impact factor: 9.410
Authors: Gerard A Silvestri; Anne V Gonzalez; Michael A Jantz; Mitchell L Margolis; Michael K Gould; Lynn T Tanoue; Loren J Harris; Frank C Detterbeck Journal: Chest Date: 2013-05 Impact factor: 9.410
Authors: Pino Alcantara; Beatriz Cabeza Martínez; Marta García García-Esquinas; Laura G Belaústegui; Ana Bustos Journal: J Clin Transl Res Date: 2020-10-06
Authors: Prashant Chandrasekharan; Zhi Wei Tay; Daniel Hensley; Xinyi Y Zhou; Barry Kl Fung; Caylin Colson; Yao Lu; Benjamin D Fellows; Quincy Huynh; Chinmoy Saayujya; Elaine Yu; Ryan Orendorff; Bo Zheng; Patrick Goodwill; Carlos Rinaldi; Steven Conolly Journal: Theranostics Date: 2020-02-10 Impact factor: 11.600